Real World Evidence Solutions Market – Component (Services, Data sets), Application (Drug Development and Approvals, Post-Market Surveillance) Revenue Model (Subscription, Pay per use), Deployment Model, End User & Forecast 2024 ­ 2032

Report Content Chapter 1 Methodology & Scope 1.1 Market scope & definitions 1.2 Research design 1.2.1 Research approach 1.2.2 Data collection methods 1.3 Base estimates & calculations 1.3.1 Base year calculation 1.3.2 Key trends for market estimation 1.4 Forecast model 1.5 Primary research and validation 1.5.1 Primary sources 1.5.2 Data mining sources Chapter 2 Executive Summary 2.1 Industry 360-degree synopsis Chapter 3 Industry Insights 3.1 Industry ecosystem analysis 3.2 Industry impact forces 3.2.1 Growth drivers 3.2.1.1 Growing focus towards accelerating drug development and cost reduction 3.2.1.2 Growing demand for real-time safety and efficacy monitoring of drugs and medical devices 3.2.1.3 Increasing adoption of RWE Solutions for informed reimbursement decision-making 3.2.1.4 Increasing adoption of data analytics services in clinical decision making 3.2.2 Industry pitfalls & challenges 3.2.2.1 Lack of standardization in integration and interoperability of real-world data 3.2.2.2 Shortage of skilled professionals 3.3 Growth potential analysis 3.4 Technology landscape 3.5 Regulatory landscape 3.6 Porter's analysis 3.7 PESTEL analysis Chapter 4 Competitive Landscape, 2023 4.1 Introduction 4.2 Company matrix analysis 4.3 Company market share analysis 4.4 Competitive positioning matrix 4.5 Strategic dashboard Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn) 5.1 Key trends 5.2 Services 5.3 Data sets 5.3.1 Disparate data sets 5.3.1.1 Clinical settings data sets 5.3.1.2 Claims data sets 5.3.1.3 Pharmacy data sets 5.3.1.4 Patient powered data sets 5.3.1.5 Registry-based data sets 5.3.2 Integrated data sets Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn) 6.1 Key trends 6.2 Drug development and approvals 6.2.1 Oncology 6.2.2 Cardiovascular disease 6.2.3 Neurology 6.2.4 Immunology 6.2.5 Other therapeutic areas 6.3 Medical device development and approvals 6.4 Post-market surveillance 6.5 Market access & reimbursement/coverage decision-making 6.6 Clinical & regulatory decision-making Chapter 7 Market Estimates and Forecast, By Revenue Model, 2021 - 2032 ($ Mn) 7.1 Key trends 7.2 Pay-per-use (value-based pricing) 7.3 Subscription Chapter 8 Market Estimates and Forecast, By Deployment Model, 2021 - 2032 ($ Mn) 8.1 Key trends 8.2 On-premise 8.3 Cloud-based Chapter 9 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn) 9.1 Key trends 9.2 Pharmaceutical and medical device companies 9.3 Healthcare payers 9.4 Healthcare providers 9.5 Other end users Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn) 10.1 Key trends, by region 10.2 North America 10.2.1 U.S. 10.2.2 Canada 10.3 Europe 10.3.1 Germany 10.3.2 UK 10.3.3 France 10.3.4 Spain 10.3.5 Italy 10.3.6 Netherlands 10.3.7 Rest of Europe 10.4 Asia Pacific 10.4.1 Japan 10.4.2 China 10.4.3 India 10.4.4 South Korea 10.4.5 Australia 10.4.6 Rest of Asia Pacific 10.5 Latin America 10.5.1 Brazil 10.5.2 Mexico 10.5.3 Rest of Latin America 10.6 Middle East and Africa 10.6.1 South Africa 10.6.2 UAE 10.6.3 Saudi Arabia 10.6.4 Rest of Middle East and Africa Chapter 11 Company Profiles 11.1 Aetion, Inc. 11.2 Cognizant Technology Solutions Corporation 11.3 Elevance Health, Inc. 11.4 Fortrea Inc. 11.5 ICON plc. 11.6 IQVIA Holdings Inc. 11.7 Merative 11.8 Optum, Inc. 11.9 Oracle Corporation 11.10 Parexel International Corporation 11.11 PerkinElmer Inc. 11.12 SAS Institute Inc. 11.13 Syneos Health, Inc. 11.14 Thermo Fisher Scientific Inc. 11.15 TriNetX LLC